Industry News: Expanding Commercialization of Novel Micro-Chip Device for Biomarker, Diagnostic and Drug Development Applications

02 Feb 2018

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, has announced that it has raised 7.3 million euro. The company will focus on intensifying international growth, supported by initial, promising sales.

Micro-Chip chromatography company PharmaFluidics closed a financing round of 7.3 million euro from investors including holding company FPIM-SFPI, and family offices Heran (Annie Vereecken) and RMM (Rudi Mariën). The existing investors PMV, Qbic, Theodorus, Innovation Fund and Volksvermogen reaffirm their confidence in the company and also participated in this financing round.

The VUB spin-off is a disruptive player in the field of micro-Chip Chromatography. Their unique technology – the µPAC™ column series – offers unprecedented robustness and reproducibility as well as state-of-the-art sensitivity and resolution performance. The first clients – academic labs in bio-analysis, bio-pharmaceuticals and diagnostics companies – have confirmed these outstanding characteristics of the µPAC™ technology.

Visit our Separations Community to find out more about nanoLC >>

The new funds will be used to further develop the Pillar Array technology platform, to expand the µPAC™product range, and to scale up production and global sales. “This funding will significantly boost our capacity to support our growth,” said PharmaFluidics’ Managing Director Johan Devenyns.

Intensified commercialization

The company started shipping µPAC™ columns in September 2017 and has since served proteomics laboratories, medical centers and pharmaceutical companies on three continents: Europe, the USA and Asia. Its pioneering product is very well received and has convinced pioneer users and key opinion leaders in proteomics to use micro-Chip based chromatography.

The unique performance of the µPAC™ columns brings groundbreaking applications within reach. For example, the robustness and reproducibility allow proteomics data from different labs to be pooled, making reliable big data analysis possible. The miniaturization and sensitivity open the door to point-of-care nano-LC-MS, or ultimately single-cell analyses. This market validation as well as the additional potential in new markets have convinced serial life sciences investors RMM SA and Heran BVBA to participate in the current funding round.


Do you use µPAC™ columns in your laboratory? Submit a review today for your chance to win $400 in Amazon vouchers.